Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Active RA Despite MTX
NCT00207714Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2003
- Primary completion
- Feb 2005
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of golimumab in rheumatoid arthritis (RA) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 20 Response at 16 weeks. Started Nov 2003; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00207714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207714.